Recombinant Human FGFBP2 Protein (Sumo Tag) (PDEH101150)
For research use only.
| Species | Human |
| Expression Host | E.coli |
| Sequence | Gln20-Gly223 |
| Accession | Q9BYJ0 |
| Calculated Molecular Weight | 37.33 kDa |
| Observed Molecular Weight | 40 kDa |
| Tag | N-Sumo |
| Bio-activity | Not validated for activity |
| Purity | > 85% as determined by reducing SDS-PAGE. |
| Endotoxin | < 10 EU/mg of the protein as determined by the LAL method |
| Storage | Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months. |
| Shipping | This product is provided as lyophilized powder which is shipped with ice packs. |
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol. |
| Reconstitution | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis. |
| Background | FGFBP2 (Fibroblast Growth Factor Binding Protein 2), a secreted chaperone, regulates fibroblast growth factors (FGFs)—key signaling molecules critical for tissue repair, angiogenesis, and cell proliferation—by binding specific ligands (e.g., FGF-1, FGF-2) through a conserved domain to enhance their release from extracellular storage or receptor interactions. Primarily expressed in regenerative or metabolically active tissues (e.g., liver, kidney, epithelia), FGFBP2 is tightly controlled under normal conditions but often overexpressed in cancers, where it amplifies FGF-driven tumor progression by promoting angiogenesis, survival, and metastasis, while also being implicated in metabolic disorders and inflammation through potential links to insulin resistance and fibrosis. Though functionally overlapping with its paralog FGFBP1, FGFBP2 exhibits distinct tissue-specific expression and ligand preferences, with ongoing research focused on elucidating its mechanistic roles in FGF signaling and exploring its therapeutic or biomarker potential in cancer and FGF-associated diseases. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
